112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

Journal article

Peer reviewed

G. Garcia-Manero, P. Fenaux, A. Al-Kali, M.R. Baer, M. Sekeres, G. Roboz, G. Gaidano, B. Scott, P. Greenberg, U. Platzbecker, …

Leukemia research, Vol.39, pp.S57-S58

2015-04

Metrics

1 Record Views

This output has contributed to the advancement of the following goals:

Source: InCites

Title: 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)
Creators: G. Garcia-Manero
P. Fenaux
A. Al-Kali
M.R. Baer
M. Sekeres
G. Roboz
G. Gaidano
B. Scott
P. Greenberg
U. Platzbecker
D.P. Steensma
S. Kambhampati
K.A. Kreuzer
L. Godley
R. Collins
E. Atallah
N. Azarnia
M.E. Petrone
B.R. Snyder
M. Maniar
L.R. Silverman
Publication Details: Leukemia research, Vol.39, pp.S57-S58
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757388302976